ArticleInfection and drug resistance2026
Protective Effect of Xuebijing Injection on Gastrointestinal Function in Septic Patients of Non-Gastrointestinal Origin.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The purpose of this study was to assess the 28-day prognosis and gastrointestinal protection of early Xuebijing in non-gastrointestinal sepsis. Methods: Septic patients with infection origins outside the gastrointestinal system and no history of acute gastrointestinal injury (AGI) were included in this single-center retrospective analysis. The two groups' baseline characteristics were balanced by propensity score matching (PSM). Secondary objectives were organ function, enteral nutrition tolerance, inflammatory markers, AGI onset time, and clinical outcomes. The primary endpoint was the incidence of 28-day AGI. Results: After matching, each group had 87 patients, and the baseline variables were evenly distributed among them ( Conclusion: Xuebijing use initiated within 24 hours of sepsis diagnosis in septic patients without pre-existing AGI was associated with protection of gastrointestinal function and improvement in several secondary outcomes, including lower AGI incidence, shorter hospital stays, reduced inflammation and organ dysfunction, and better enteral nutrition outcomes, without additional safety concerns. However, no significant difference in 28-day mortality was observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.